

**Glaucoma Update: Cases and Controversies: Expert Advice on Navigating Challenging Situations (2/4/2023 @ 8 a.m. ET)**

**Saturday, February 4, 2023**

*Wills Eye Auditorium*

**[Conference Description:](https://attendee.gotowebinar.com/register/5951770118456799575%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)**

[Register for Livestream Reminders Here!](https://attendee.gotowebinar.com/register/5951770118456799575%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

[With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.](https://attendee.gotowebinar.com/register/5951770118456799575%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

**At the conclusion of the course, participants should be able to:**

1 Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of glaucoma.

2 Identify basic and clinical vision research that can be transformed into improved clinical care.

2 Describe factors that impact the effective delivery of the highest quality glaucoma care for the public.

3 Assess the role of new technologies in the evaluation and treatment of eye diseases.

3 Obtain information and tools through multiple facets to help glaucoma specialists deliver high and efficient quality of care.

5 Identify clinical, scientific, and ethical issues confronting the profession.

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Wills Eye Hospital designates this live educational activity for a maximum of 4.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of Ineligible Company(s) / Nature of Relationship(s)** |
| Shaunna Lee, MD | Activity Administrator | Nothing to disclose - 10/12/2022 |
| Ethan C Heck, MD | Activity Coordinator | Nothing to disclose - 11/03/2022 |
| Michael Pro, MD | Course Director, Faculty | Nothing to disclose - 01/24/2023 |
| Elizabeth Dale, MD | Faculty | Nothing to disclose - 01/03/2023 |
| Jason Flamendorf, MD | Faculty | Nothing to disclose - 01/24/2023 |
| Lauren Hock, MD | Faculty | Nothing to disclose - 11/10/2022 |
| Natasha Kolomeyer, MD | Faculty | Consulting Fee-Allergan (Relationship has ended)|Grant or research support-Allergan|Grant or research support-Guardion Health Services Inc|Grant or research support-Nicox|Grant or research support-Olleyes|Grant or research support-Santen Pharmaceuticals|Grant or research support-Glaukos Corporation|Grant or research support-Diopsys|Grant or research support-Aerie Pharmaceuticals - 01/08/2023 |
| Lindsay Machen, MD | Faculty | Nothing to disclose - 01/08/2023 |
| Jonathan S. Myers, MD | Faculty | Consulting Fee-Aerie Pharmaceuticals (Relationship has ended)|Consulting Fee-Allergan (Relationship has ended)|Consulting Fee-Glaukos Corporation (Relationship has ended)|Grant or research support-Allergan|Grant or research support-Glaukos Corporation|Grant or research support-Nicox|Grant or research support-Santen Pharmaceuticals|Grant or research support-Guardian|Grant or research support-Haag Streit (Relationship has ended)|Grant or research support-Laboratories Thea Inc - 11/13/2022 |
| Reza Razeghinejad, MD | Faculty | Grant or research support-Olleyes - 01/04/2023 |
| Jesse Richman, MD | Faculty | Consulting Fee-Alcon|Royalties or Patent Beneficiary-Visionology|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Visionology|Paid consultant-Allergan (Relationship has ended) - 01/03/2023 |
| Zeba A. Syed, MD | Faculty | Speakers Bureau-Bio-Tissue|Grant or research support-Glaukos Corporation - 10/14/2022 |
| Douglas Wisner, MD | Faculty | Advisor-Zeiss|Advisor-Haag-Streit - 03/25/2022 |
| Cindy Zheng , MD | Faculty | Nothing to disclose - 10/25/2022 |
| Ralph C. Eagle Jr., MD | Other Planning Committee Member | Stocks or stock options, excluding diversified mutual funds-Merck - 06/07/2022 |

